Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Can-Fite BioPharma Ltd. CANF

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$405,000
▼ 39.9% YoY
$-9.8M
$-9.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. Our product candidates, CF101, CF102 and CF602, are being developed to treat oncological and inflammatory diseases, as well as erectile dysfunction. CF101, also known as Piclidenoson, is in an advanced stage of clinical development for the treatment of psoriasis. CF102, also known as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for this indication in the United States and Europe.

Written from the business description in Can-Fite BioPharma Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth

USD 405,000.00
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.4 · Net income -9.8
2M3M-10M-20M
2018202120242025
Compound annual growth
−20.6%
−11.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −11.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -2456.8% · Net ·
-1000%-2000%
201820212025
ROE
FY2025 · ROE -178.2%
-200%-400%
201820212025
Three returns, three denominators.

Each USD of equity lost 178 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -9.0
-5M-10M
201820212025
Net buybacks $M Dividends $M
FY2021 · Dividends 2.6 · Net buybacks ·
1M2M
20202021

Total assetsUSD 9.5M
EquityUSD 5.6M
CashUSD 5.5M
Current ratio3.46×

Equity funds 59% of total assets.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CANF, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−5.97−10.86−17.92−0.01−0.03−0.04−0.14−0.17
Dividend / sh $◌◌◌◌◌◌◌◌
Payout %————−21−5——
ROE %−178.2−134.9−142.5−107.9−123.3−339.2−462.7−219.1
Shares out B0.000.001.360.820.820.460.12◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 31 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image